Skip to main content
Clinical Trials/NCT01072058
NCT01072058
Unknown
Phase 4

Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker

University of Sao Paulo1 site in 1 country100 target enrollmentFebruary 2008

Overview

Phase
Phase 4
Intervention
TNF blockers (infliximab, adalimumab, etanercept)
Conditions
Arthritis, Rheumatoid
Sponsor
University of Sao Paulo
Enrollment
100
Locations
1
Primary Endpoint
Development, deterioration ou improvement of subclinical heart dysfunction
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.

Registry
clinicaltrials.gov
Start Date
February 2008
End Date
February 2011
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Julio Moraes, MD

MD

University of Sao Paulo

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Rheumatoid Arthritis eligible to receive TNF blockers
  • Diagnosis of Ankylosing Spondylitis eligible to receive TNF blockers

Exclusion Criteria

  • Clinical heart failure
  • Chagas'disease
  • Stable or unstable angina
  • Past history of myocardial infarct
  • Systemic árterial hypertension (grade 3)
  • Valvulopathy
  • Chronic kidney disease

Arms & Interventions

TNF blockers

Intervention: TNF blockers (infliximab, adalimumab, etanercept)

Outcomes

Primary Outcomes

Development, deterioration ou improvement of subclinical heart dysfunction

Time Frame: 0, 6 ,12, 18 and 24 months

Study Sites (1)

Loading locations...

Similar Trials